Simply HPV™2023-10-12T17:54:17+00:00

Human Papilloma Virus (HPV)

Human Papilloma Virus (HPV)

SimplyTest PERIO

SimplyHPV ™

  • Physician ordered testing

  • For women

  • Pain-free vaginal specimen self-collection brush

  • Free Shipping

  • Results in 24-48 hours after received at the lab

  • Consistent, highly accurate, & dependable molecular testing

  • Actionable clinical insights

  • CAP/CLIA accredited testing laboratory

  • HPV-16
  • HPV-18
  • HPV-31
  • HPV-33
  • HPV-35
  • HPV-39
  • HPV-45
  • HPV-51
  • HPV-52
  • HPV-56
  • HPV-58
  • HPV-59
  • HPV-66
  • HPV-68

HPV-16 and HPV-18 are the most recognized HPV strains for causing genital cancer. SimplyHPV™ does not detect types of HPV that are not considered high risk for cancer development.

WHY TEST?

Consider these burden of disease facts. Worldwide, in 2018, the 4th most common cause of new cancer cases in women, as well as the 4th most common cause of cancer death for women is tied to HPV.1,2

In 2020, According to the American Cancer Society Journal (ACSJ), cervical cancer was again named the fourth most frequently diagnosed cancer and the fourth leading cause of cancer death in women.

An estimated 604,000 women were diagnosed with cervical cancer worldwide and about 342,000 women died from the disease in 2020. In addition, cervical cancer is the most commonly diagnosed cancer in 23 countries.3

Within the United States, cervical cancer death rates are 2-fold higher among women residing in high-poverty versus low-poverty areas.3

  1. Cronin KA, Lake AJ, & Scott S, et al. Cancer 2018 Jul 1;124(13):2785–2800 Centers for Disease Control. Preventing Cervical Cancer in the 21st Century. Accessible Version:20190125-presentation-cervical-cancer-H.pdf
  2. www.cancer.org/content/dam/cancer-org/research/cancer-facts-and-statistics/global-cancer-facts-and-figures/global-cancer-facts-and-figures-4th-edition.pdf gco.iarc.fr/today/data/factsheets/populations/900-world-fact-sheets.pdf
  3. Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021;71:209–49. doi:10.3322/caac.21660. (American Cancer Society https://acsjournals.onlinelibrary.wiley.com/doi/10.3322/caac.21660)

Cervical Cancer is Considered Nearly Completely Preventable.

CDC estimates that about 80 million people are currently infected with HPV in the United States and about 14 million people in the US get a new HPV infection every year.

Identifying those with persistent infection and contributing cofactors before the onset of dysplasia is key to reducing the incidence of HPV related cancer.

SimplyTest
SimplyTest White Logo

Satterwhite CL, Torrone E, Meites E, et al. Sex Transm Dis 2013 Mar;40(3):18793 Winer RL, Lee SK, Hughes JP, et al. Am J Epidemiol 2003;157:218–2

Cervical Cancer is Considered Nearly Completely Preventable.

CDC estimates that about 80 million people are currently infected with HPV in the United States and about 14 million people in the US get a new HPV infection every year.

Identifying those with persistent infection and contributing cofactors before the onset of dysplasia is key to reducing the incidence of HPV related cancer.

SimplyTest
SimplyTest White Logo

Satterwhite CL, Torrone E, Meites E, et al. Sex Transm Dis 2013 Mar;40(3):18793 Winer RL, Lee SK, Hughes JP, et al. Am J Epidemiol 2003;157:218–2

WHO TO TEST?

High-quality screening programs are important to prevent cervical cancer among unvaccinated women and for oncogenic subtypes not covered by the vaccine. In the absence of effective screening, there have been rapid increases in premature cervical cancer mortality.1

Using an HPV DNA NAAT as the primary screening test prevents more cervical cancers and saves more lives than using visual inspection with acetic acid (VIA) or cytology (conventional Pap smear and liquid-based cytology) as the primary screening test.2

Accumulated evidence supports the use of HPV-based tests for the detection of precancerous lesions as a preferred test for primary screening. According to the World Health Organization (WHO) continuing screening is crucial and existing programs with quality-assured cytology or VIA as primary screening tests should be continued until access to HPV NAATs screening, like the SimplyHPV™ test, are able to replace them.

  1. Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021;71:209–49. doi:10.3322/caac.21660. (American Cancer Society https://acsjournals.onlinelibrary.wiley.com/doi/10.3322/caac.21660)
  2. Human papillomavirus (HPV) nucleic acid amplification tests (NAATs) to screen for cervical pre-cancer lesions and prevent cervical cancer: policy brief ISBN 978-92-4-004524-8 (electronic) ISBN 978-92-4-004525-5 (print)

Recommended Testing Guidelines

The goal of cervical screening is to find cervical diseases, pre-cancer, or cancer early when it is more easily treatable. Regular screening can prevent cervical cancer and save lives.

(Click chart image to enlarge)

HPV Testing Guidelines

Meet the Lab

FAQ’s

Frequently Asked Questions

What does SimplyHPV™ test for?2023-10-12T17:50:21+00:00

The test specifically identifies HPV 16 & HPV 18 while concurrently detecting (31, 33, 35, 39, 45, 51, 56, 58, 59, 66, and 68).

What is SimplyHPV™?2023-10-12T17:48:36+00:00

SimplyHPV™ is a test for the qualitative and simultaneous molecular detection of 14 high-risk HPV types in a single test.

What are Monkeypox (Mpox) testing and re-testing CDC Recommendations?2023-03-22T00:58:14+00:00

  • “Test-of-cure” follow-up testing recommendations are not established for monkeypox.
  • Coinfection rates of monkeypox with other STIs and HIV are extremely high — approximately 40% for person’s diagnosed with monkeypox are coinfected with another STI or HIV.
  • The CDC recommends that any person diagnosed with monkeypox, also be tested for other STI infections and HIV.

Coinfection of monkeypox and HIV is common. About 40% of monkeypox patients have HIV. Any persons diagnosed with monkeypox should also be tested for HIV. Coinfection of monkeypox and other STIs is also common. Approximately 40% of monkeypox patients have been diagnosed with another STI within the preceding year. Any persons diagnosed with monkeypox should also be tested for other STI infections. (CDC)

 

What are Nisseria Gonorrhea (NG) testing and re-testing CDC Recommendations?2023-03-22T00:49:51+00:00

  • “Test-of-cure” follow-up testing is not recommended for genital and rectal infections unless symptoms persist.
  • “Test-of-cure” is recommended 7–14 days following treatment for oral gonorrhea infections.
  • Because re-infection is common, the CDC recommends that men and women diagnosed with gonorrhea be retested three months after treatment.

A test-of-cure – follow-up testing to be sure the infection was treated successfully – is not needed for genital and rectal infections; however, if a person’s symptoms continue for more than a few days after receiving treatment, he or she should return to a health care provider to be reevaluated. A test-of-cure is needed 7-14 days after treatment for people who are treated for a throat infection. Because re-infection is common, men and women with gonorrhea should be retested three months after treatment of the initial infection, regardless of whether they believe that their sex partners were successfully treated.

Gonorrhea can be cured with the right treatment. CDC recommends a single dose of 500 mg of intramuscular ceftriaxone. Alternative regimens are available when ceftriaxone cannot be used to treat urogenital or rectal gonorrhea. Although medication will stop the infection, it will not repair any permanent damage done by the disease. Antimicrobial resistance in gonorrhea is of increasing concern, and successful treatment of gonorrhea is becoming more difficult.

SimplyTest™

TESTING MENU

CONTACT US

© Copyright  Spectrum Solutions®  |   Alimetrix®, SimplyTest®, & Spectrum Solutions® are registered trademarks of Spectrum Solutions, LLC.  |   Alimetrix, Inc. is a CAP Accredited and CLIA Certified Molecular Diagnostic Laboratory | All Rights Reserved 
Toggle Sliding Bar Area

Your Provider Portal Account

Easily advance your clinical testing program today.

> Ordering testing supplies is done from inside your provider portal account.

> Leave us a Message

ACCREDITATIONS

CAP #9450297

CLIA #01D2113023

This website uses cookies to help improve our site's user experience. We store personal information for only as long as we have a reason to keep it. We are thoughtful about the information we ask you to provide and collect through the operation of our business services. All information collected is never shared with third parties or used for any purpose outside of what our company delivers. In addition, info and can be deleted from our system upon request. Ok